期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Research on the World’s Most Valuable Antihypertensive Drugs Based on Patent Analysis
1
作者 Zhang Tianqi Chen Yuwen 《Asian Journal of Social Pharmacy》 2021年第1期76-83,共8页
Objective To find out several patented technologies of antihypertensive drugs with the most market value through analysis,and provide a reference for the research and development of enterprises.Methods The most valuab... Objective To find out several patented technologies of antihypertensive drugs with the most market value through analysis,and provide a reference for the research and development of enterprises.Methods The most valuable patented technologies of antihypertensive drugs from 2009 to 2019 were analyzed to explore the patent layout and technical characteristics of the main patent applicants,and then the key directions of their research and development were gotten.Results and Conclusion Based on the method of patent analysis,five patents with the most market value are extracted to provide important technical support and market value reference for the research and development of generic drugs or new drugs. 展开更多
关键词 antihypertensive drug patented generic drug patented technology market value
下载PDF
Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984 被引量:4
2
作者 Garth Boehm Lixin Yao +1 位作者 Liang Han Qiang Zheng 《Acta Pharmaceutica Sinica B》 SCIE CAS 2013年第5期297-311,共15页
The key events in the development of the US generic drug industry after the Hatch-Waxman Act of 1984 are systematically reviewed,including the process of approval for generic drugs,bioequivalence issues including“swi... The key events in the development of the US generic drug industry after the Hatch-Waxman Act of 1984 are systematically reviewed,including the process of approval for generic drugs,bioequivalence issues including“switchability”,bioequivalence for complicated dosage forms,patent extension,generic drug safety,generic substitution and low-cost generics.The backlog in generic review,generic drug user fees,and“quality by design”for generic drugs is also discussed.The evolution of the US generic drug industry after the Hatch-Waxman Act in 1984 has afforded several lessons of great benefit to other countries wishing to establish or re-establish a domestic generic drug industry. 展开更多
关键词 Generic drugs drug Price Competition and Patent Term Restoration Act Abbreviated new drug application BIOEQUIVALENCE drug quality Generic drug substitution
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部